Sentiment Trading

Galectin Therapeutics Inc. sees promising developments with the release of NAVIGATE study results, coinciding with favorable market growth projections for liver fibrosis treatments.

Galectin Therapeutics Inc. is set to showcase its innovations at the EASL Congress, highlighting its progress in developing therapies for fibrotic diseases and cancer.